Verona.jpg
Verona Pharma to Present Expanded Analysis of Phase 2b COPD Data with Ensifentrine at the American Thoracic Society 2021 International Conference
May 04, 2021 02:00 ET | Verona Pharma plc
LONDON and RALEIGH, N.C., May 04, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces...
Verona.jpg
Verona Pharma Reports First Quarter 2021 Financial Results and Provides Corporate Update
April 29, 2021 02:00 ET | Verona Pharma plc
ENHANCE Phase 3 program enrollment continues on track to complete in 2H21 Board strengthened with NED appointment of Lisa Deschamps Conference call today at 9:00 a.m. EDT / 2:00 p.m. BST LONDON and...
Verona.jpg
Verona Pharma Announces Publication of Phase 2b Dose-Ranging COPD Data in the International Journal of Chronic Obstructive Pulmonary Disease
April 27, 2021 02:00 ET | Verona Pharma plc
LONDON and RALEIGH, N.C., April 27, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces...
Verona.jpg
Verona Pharma Reports Results of Pilot Study of pMDI Ensifentrine in U.S. Patients Hospitalized with COVID-19
April 23, 2021 02:00 ET | Verona Pharma plc
LONDON and RALEIGH, N.C., April 23, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces...
Verona.jpg
Verona Pharma to Report First Quarter 2021 Financial Results and Provide Corporate Update
April 21, 2021 02:00 ET | Verona Pharma plc
LONDON and RALEIGH, N.C., April 21, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces...
Verona.jpg
Lisa Deschamps Joins Verona Pharma as Non-Executive Director
March 02, 2021 02:00 ET | Verona Pharma plc
LONDON and RALEIGH, N.C., March 02, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases,...
Verona.jpg
Verona Pharma to Present at H.C. Wainwright Global Life Sciences Virtual Conference
March 01, 2021 02:00 ET | Verona Pharma plc
LONDON and RALEIGH, N.C., March 01, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces...
Verona.jpg
Verona Pharma Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update
February 25, 2021 02:00 ET | Verona Pharma plc
Positive Phase 2 results with pMDI ensifentrine in COPD Enrollment ongoing in ENHANCE Phase 3 program  Up to $30 million debt finance facility increases financial flexibility Conference...
Verona.jpg
Verona Pharma to Report Fourth Quarter and Full Year 2020 Financial Results and Provide Corporate Update
February 18, 2021 02:00 ET | Verona Pharma plc
LONDON and RALEIGH, N.C., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces...
Verona.jpg
CORRECTING and REPLACING -- Verona Pharma Reports Positive Phase 2 Results with pMDI Formulation of Ensifentrine in COPD
February 02, 2021 06:17 ET | Verona Pharma plc
LONDON and RALEIGH, N.C., Feb. 02, 2021 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by Verona Pharma plc (Nasdaq: VRNA), please note that all instances of the unit...